TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05774405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Climara 0.1Mg/24Hr Transdermal System
Description: Transdermal estradiol patch is used.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogel patch
Description: Adhesive Hydrogel patch
Study: NCT00649493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Tablets 20 mg
Description: 20mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex® Tablets 20 mg
Description: 20mg, single dose fed
Study: NCT01161004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex - Nacl 9/00
Description: * Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~* Nacl 9/00: same volume as Sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nacl 9/00 - sugammadex
Description: * Nacl 9/00: same volume as Sugammadex~* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.
Study: NCT03125941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: pre-operative intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: pre-operative intravenous administration
Study: NCT00582491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil 400mg orally every day for 16 days
Study: NCT03257878

Intervention type: OTHER
Intervention: validated Korean version of the SF36 and EQ-5D
Description: This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

Intervention type: OTHER
Intervention: validated Korean version of the SF36 and EQ-5D
Description: This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).
Study: NCT00582491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally everyday for 16 days
Study: NCT04587349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation
Description: Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation
Description: Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy 2-years-long (3/week)
Study: NCT00874328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan iv D1 q 3 weeks until maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 (S-1)
Description: TS-1 po D1\~D14 q 3 weeks until maximum 6 cycles
Study: NCT03698760

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Olfactory test
Description: Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way.
Study: NCT01367600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Study: NCT00426140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study: NCT04198285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde bladder filling
Description: The bladder will be filled with a large syringe through the urinary catheter (which is left in place for the surgery) with 200mL of sterile saline, and then the catheter will be removed.
Study: NCT03616561

Intervention type: DRUG
Intervention: Apremilast
Description: Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
Study: NCT01871402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 000-0551 Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Study: NCT00565916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen
Description: Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
Study: NCT03736330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combinations treatment
Description: Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck \& Co., Inc.） and were transferred to participants via intravenous infusion .
Study: NCT04417140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dHACM (AmnioWrap)
Description: Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
Study: NCT00977704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane and Perlane
Study: NCT02222675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonography assisted breast surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional breast surgery
Study: NCT03112668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Undergo ACT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00857597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Incisionless Fundoplication
Description: The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton Pump Inhibitors; active control
Description: Proton Pump Inhibitors; active control
Study: NCT00431873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 Administered orally three times per week.
Study: NCT03247764

Intervention type: OTHER
Description: observational study
Study: NCT00369200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFP464
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study: NCT02544295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality task
Study: NCT03595358

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ellume Home Flu Test
Description: The Ellume Home Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ellume.lab Flu A+B Test
Description: The ellume.lab Flu A+B Test is a rapid in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Description: Reverse Transcriptase Polymerase Chain Reaction (RT_PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Viral culture
Description: Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
Study: NCT02223819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration.
Study: NCT03274557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFM
Study: NCT04134065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: patients with refractory Crohn disease and a serum 25(OH)D concentration \<75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: the capsule contain nothing
Study: NCT01103947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EcoAnaesthesia facemask first
Description: The trial facemask will be used before the standard one.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portex Adult (Standard) facemask first
Description: The standard facemask will be applied before the trial device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portex Adult (Standard) facemask second
Description: The standard facemask will be applied after the trial device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EcoAnesthesia facemask second
Description: The trial facemask will be used after the standard one.
Study: NCT04512313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,3mg/kg
Description: Rocuronium 0,3mg/kg at induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,9mg/kg
Description: Rocuronium 0,9mg/kg at induction
Study: NCT01471717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189 50 mg QD X 5 days
Description: Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INX-08189 / Victrelis 800 mg TID X three days
Description: Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victrelis 800 mg TID x 3 days
Description: In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victrelis 800 mg TID with INX-08189 50 mg QD
Description: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with Victrelis 800 mg
Description: During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 2: Victrelis 800 mg with Placebo
Description: During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
Study: NCT02405975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCRIPT
Description: An online tool designed to train doctors in all areas of prescribing
Study: NCT00955045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: istradefylline
Study: NCT01397539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB037
Description: Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
Study: NCT00355706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic facet joint nerve blocks
Description: Thoracic medial branch blocks
Study: NCT00110513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin (rhAT)
Description: Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is \> 80% and \< 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at \> 80% and \< 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
Study: NCT00057603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
Study: NCT03154840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU
Description: Investigate the Relative Bioavailability among Different Eutropin Formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU
Description: Investigate the Relative Bioavailability among Different Eutropin Formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU
Description: Investigate the Relative Bioavailability among Different Eutropin Formulations
Study: NCT03300375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Home-based, progressive exercise program using resistance bands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home-based, progressive exercise program using resistance bands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Op instructions
Description: Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
Study: NCT00001626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Description: antithymocyte globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: cyclosporine
Study: NCT04513457

Intervention type: OTHER
Intervention: Liver resection and Neoadjuvant chemotherapy

Intervention type: OTHER
Intervention: Liver resection and Adjuvant chemotherapy

Intervention type: OTHER
Intervention: Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy

Intervention type: PROCEDURE
Intervention: Liver resection
Study: NCT02343588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Health Lifestyles Interventions
Description: 1. Creating supportive school and family environment, whole intervention periods;~2. Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;~3. Instruct and promote school physical education, whole intervention periods;~4. The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor
Study: NCT03898180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for lenvatinib
Description: oral capsule
Study: NCT00953095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Attention Intervention
Description: Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Attention Intervention
Description: Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
Study: NCT03562351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Instructions Educational Intervention
Description: Caregivers will undergo training with verbal instructions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Educational Intervention
Description: Caregivers will undergo training with an educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mannequin Educational Intervention
Description: Caregivers will undergo training with a mannequin